TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05965505
Drug: AXT-1003
Normalized name: Axtle
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
Study: NCT04873479
Drug: S-ketamine
Normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants in the test group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine 0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of sevoflurane at 2-3%.
Study: NCT06182592
Drug: Liposomal cytarabine-daunorubicin for injection
Normalized name: cytarabine / daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: First induction: 100 units/m\^2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m\^2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m\^2 by 90-minute IV infusion on Days 1 and 3.
Study: NCT06182592
Drug: 7+3 (cytarabine and daunorubicin)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First induction: 7+3 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1, 2, and 3.~Second induction: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2.~Consolidation therapy: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2.
Study: NCT04114890
Drug: Tenofovir Disoproxil Fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir Disoproxil Fumarate 300 mg once daily and will continue until one month after delivery
Study: NCT05590013
Drug: Pectointercostal and ESP block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pectointercostal plane block will apply at the 4-5. intercostal space and ESP block will apply athe T6 level bilaterally
Study: NCT04997811
Drug: Sodium Valproate, Bezafibrate, Medroxyprogesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium valproate tablet 1 x 500mg bd, (starting 1 x 200mg bd) Bezafibrate standard release tablet 2 x 200mg tds, (starting 1 x 200mg tds) Medroxyprogesterone acetate tablet 1 x 400mg bd (starting 1 x 400mg od)
Study: NCT04997811
Drug: Danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 1 x 200mg capsules tds, (starting 1 x 200mg od)
Study: NCT05181683
Drug: Casirivimab+Imdevimab
Normalized name: casirivimab / imdevimab
DrugBank: Imdevimab (DB15940)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration
Study: NCT05554094
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 15 mg of oral psilocybin in the first session and 25 mg in the second session.
Study: NCT04976751
Drug: Percutaneous electrical nerve stimulation treatment
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using the percutaneous electrical nerve stimulation instrument to different points of the body
Study: NCT06258356
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: novel ultra-short-acting benzodiazepine-like anesthetic.
Study: NCT05933395
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant will be administered intramuscularly into the buttocks in combination with one of the other interventions as outlined above.
Study: NCT05933395
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
Study: NCT05933395
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpelisib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
Study: NCT05933395
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus will be administered orally in tablet form once daily in combination with fulvestrant administration as outlined above.
Study: NCT05933395
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abemaciclib will be administered orally in tablet form twice daily in combination with fulvestrant administration as outlined above.
Study: NCT04473924
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Body surface area-based dosing of mycophenolate
Study: NCT04473924
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard (fixed) dosing of mycophenolate
Study: NCT05506891
Drug: Astragalus
Normalized name: Astragalus
DrugBank: Astragalus mongholicus root polysaccharides (DB17721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a 2-week washout period, astragalus granules 15g, drunk with warm water, once a day, will be taken for 3 months.
Study: NCT05462548
Drug: Luspatercept Injectable Product
Normalized name: luspatercept Injectable Product
DrugBank: Luspatercept (DB12281)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1-1.25mg/kg every 3 weeks subcutaneous injection
Study: NCT05496868
Drug: Reparixin 600mg
Normalized name: Reparixin
DrugBank: Reparixin (DB12614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reparixin 600 mg tablets, administered crushed through nasogastric tube at the dose of 1200 mg TID (2 tablets TID administered approximately about every 8 hours) as add-on to the standard of care. After extubation and if the patient can swallow, reparixin may be administered orally. Total duration of the treatment: 14 days
Study: NCT06077786
Drug: Lu AG06474
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT06077786
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule
Study: NCT05323981
Drug: Perjeta
Normalized name: Perjeta
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous drip of 420mg PERJETA
Study: NCT04997161
Drug: Sodium Zirconium Cyclosilicate (SZC)
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants in the active arm will receive SZC dosed as per the local label to control hyperkalaemia and maintain normokalaemia.
Study: NCT05845723
Drug: tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.
Study: NCT05845723
Drug: tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive tofacitinib 5mg twice a day for 24 weeks of treatment.
Study: NCT05192369
Drug: CTP-543
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: CTP-543 12 mg (1 x 12 mg tablet), dosed with water
Study: NCT05192369
Drug: CTP-543
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: CTP-543 48 mg (4 x 12 mg tablet) dosed with water
Study: NCT05192369
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin (1 x 400 mg tablet) dosed with water
Study: NCT06505369
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be administered by SC injection
Study: NCT06505369
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be administered by SC injection
Study: NCT06505369
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide will be administered by oral route
Study: NCT06505369
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered by oral route
Study: NCT06505369
Drug: Talquetamab
Normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talquetamab will be administered by SC injection
Study: NCT06505369
Drug: Teclistamab
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab will be administered by SC injection
Study: NCT05365178
Drug: Fulvestrant injection
Normalized name: Fulvestrant Injection
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant is a competitive estrogen receptor antagonist, and its mechanism is related to the down-regulation of estrogen receptor (ER) protein level
Study: NCT05490511
Drug: Tacrolimus single dose
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg once
Study: NCT05490511
Drug: Epidiolex single dose
Normalized name: Epidiolex
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Epidiolex 5 mg/kg
Study: NCT05490511
Drug: Epidiolex steady-state and tacrolimus single dose
Normalized name: Epidiolex
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
Study: NCT05779644
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide is injected once a day.
Study: NCT05779644
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide is injected once a week.
Study: NCT05779644
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin is taken orally daily.
Study: NCT06254404
Drug: Low dose protamine
Normalized name: protamines
DrugBank: Protamine sulfate (DB09141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 70% of the normal dose of protamine
Study: NCT05564429
Drug: 18F-SF12051
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected intravenously followed by PET scanning
Study: NCT05392959
Drug: Dapagliflozin 10 mg Tab
Normalized name: dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg per day
Study: NCT06321887
Drug: Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron)
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks (N=10).
Study: NCT06321887
Drug: Ferrous fumarate syrup 2.5ml/70mg(45mg elemental iron)
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) daily for 8 weeks (N=10).
Study: NCT06321887
Drug: Ferrous fumarate syrup 2.5ml/70mg (90mg elemental iron)
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) for 8 weeks (N=10).
Study: NCT04702685
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic for injection
Study: NCT06332235
Drug: Silodosin 8 mg
Normalized name: silodosin 8 MG
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dosing schedule: Oral, once daily
Study: NCT05975944
Drug: Selinexor，Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose level 1: Selinexor 40mg PO QW, Olaparib 150mg PO BID; Dose level 2: Selinexor 60mg PO QW, Olaparib 150mg PO BID; Dose level 3: Selinexor 80mg PO QW, Olaparib 150mg PO BID.
Study: NCT06562920
Drug: adebrelimab and chemotherapy
Normalized name: cytarabine and daunorubicin
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of adebrelimab combined with chemotherapy and concurrent SBRT, and undergo surgery within 4-6 weeks after treatment.
Study: NCT06170723
Drug: BMS-986368
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT06170723
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06170723
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04941313
Drug: 3D229
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3D229 is an investigational drug.
Study: NCT05028478
Drug: CN202
Normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive CN202 by IV infusion on Day 1 of each cycle (once every 2 weeks). The 4 planned dose levels are 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg
Study: NCT06382662
Drug: metaxalone m640
Normalized name: Metaxalone
DrugBank: Metaxalone (DB00660)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of micronize metaxalone 640 mg
Study: NCT06382662
Drug: tizanidine
Normalized name: Tizanidine
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of tizanidine 8 mg
Study: NCT05912335
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.
Study: NCT04840472
Drug: 111I-n panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imaging Agent
Study: NCT01549548
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Ponatinib 45 mg by mouth as a single daily dose on an empty stomach (no food 2 hours prior to and after dosing) on day 1 and continuous once-daily dosing everyday thereafter. Each patient will receive daily Ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent.
Study: NCT06188546
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: trying different dosages of propofol 10mg/ml IV to determine the prophylactic dose for morphine induced pruritis
Study: NCT06446557
Drug: treatment adaptation guided by ctDNA variation
DrugBank: DAPTA (DB16290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: after 4 cycles of doublet + TA, non-progressive patients will be allocated to a strategy according to ctDNA value and variation from C1-C3: Arm A1: CT discontinuation (ctDNA normalization \< 0.1 ng/ml or ctDNA not detectable) Arm A2 : maintenance with fluoropyrimidine + TA (ctDNA ≥ 0.1 ng/ml and ∆ctDNA≥ 80%).~Arm A3 : ctDNA non-responders (∆ctDNA \< 80% or increase) : switch of CT +/- TA.
Study: NCT00939835
Drug: Citalopram Hydrobromide
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05691855
Drug: 89Zr-NY009
Normalized name: 89ZR-BEVACIZUMAB
DrugBank: Bevacizumab zirconium Zr-89 (DB14907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a tracer (5-10mg, IV) dose of 89Zr (2-3mCi) labelled NY009
Study: NCT04659304
Drug: Allocetra-OTS
Normalized name: Allocetra
DrugBank: Allocetra (DB16424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
Study: NCT04943549
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be placed in left lateral position. A low-frequency curved array ultrasound transducer will be used. The ultrasound transducer will be placed in a longitudinal orientation 2-3 cm lateral to the midline to identify the hyperechoic line of the transverse process. After identification of muscles superficial to the transverse process and local infiltration of anesthesia into the superficial tissues, a block needle will be inserted in a craniocaudal direction until contact will be achieved with the transverse process where the tip will lay in the interfascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle; the erector spinae muscle should be visualized, separating from the transverse process. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally. Forty minutes after the ESPB, the cutaneous sensory block will be assessed.
Study: NCT04937088
Drug: ASA
Normalized name: ASA
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid aspirin formulation
Study: NCT05994378
Drug: SHR7280 simulant； Ganirelix Acetate Injection
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SHR7280 simulant 200mg Q12h and Ganirelix Acetate Injection 0.5mL:0.25mg qd;
Study: NCT05428826
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase 4 Prednisone Dose : 1mg/kg/day at inclusion Route of administration : oral Duration of treatment: 9 to 21 months.
Study: NCT06393530
Drug: 0.9%sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,9% normal saline
Study: NCT06393530
Drug: 0.2% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,2% ropivacaine
Study: NCT05849389
Drug: Vosoritide
Normalized name: VOSORITIDE
DrugBank: Vosoritide (DB11928)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vosoritide administered daily via subcutaneous injection for 12 months using the FDA approved weight-based dosing band strategy for achondroplasia.
Study: NCT06018116
Drug: Bicalutamide 150 mg
Normalized name: bicalutamide 150 MG
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nonsteroidal antiandrogen
Study: NCT06030843
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 10 MG
Study: NCT05356091
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with propofol (1-1.5 mg/kg), and will be maintained with sevoflurane to keep patient state index of 25-50.
Study: NCT05356091
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam is chosen as an anesthetic agent for general anesthesia. General anesthesia for the patients in this group will be induced with remimazolam, and will be maintained with remimazolam to keep patient state index of 25-50.
Study: NCT05275699
Drug: 68Ga-FAPI
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of keloid by PET/CT.
Study: NCT00113958
Drug: Cinacalcet
Normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT06014424
Drug: CBD
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants in this arm will receive CBD for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
Study: NCT05429463
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5-6 mg/mL/min by IV infusion Q3W, given on cycle day 1.
Study: NCT05429463
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
Study: NCT00002356
Drug: Fomivirsen sodium
Normalized name: Fomivirsen Sodium
DrugBank: Fomivirsen (DB06759)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000938
Drug: ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05103345
Drug: SGN1
Normalized name: Sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SGN1,will be administered intratumorally,which dosage is 0.9-2.0×109 cfu /vial.
Study: NCT04975347
Drug: Naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One bolus and one infusion of naloxone
Study: NCT05404490
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
Study: NCT05811247
Drug: AD109
Normalized name: Adefovir dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral administration at bedtime.